Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Patients with follicular lymphoma who require therapy and have been previously untreated are
eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3
cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be
determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT
conversion rate, frequency and severity of adverse events, duration of complete remission
and time to next lymphoma therapy.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete response rate
May 2007,May 2008, May2009, May 2010
No
Samuel A Jacobs, MD
Principal Investigator
University of Pittsburgh
United States: Food and Drug Administration
UPCI #03-005
NCT00177554
November 2003
May 2007
Name | Location |
---|---|
UPMC Cancer Centers | Pittsburgh, Pennsylvania 15232 |